John Bridgewater

26PUBLICATIONS
211CO-AUTHORS
Molecular targetsCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jun 01, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

|Jan 21, 2026
Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.

William C H Cross, Salpie Nowinski, George D Cresswell

|Jan 09, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Timothy Iveson, Mark P Saunders, Caroline Kelly

|Dec 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.

Gary Middleton, Charlotte Gaskell, Joshua Savage

|Dec 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Jesus M Banales, Pedro M Rodrigues, Silvia Affò

|Oct 08, 2025
Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.

Teresa Macarulla, Cindy Neuzillet, Gerald W Prager

Pageof 5

Frequent Collaborators

11 joint publications

Juan W Valle

4 joint publications

Chiara Braconi

4 joint publications

Ann-Marie Baker

4 joint publications

Trevor A Graham